REG - Kanabo Group PLC - Launch of new products

KanaboAnnouncement

17/01/2023 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230117:nRSQ8895Ma&default-theme=true

RNS Number : 8895M  Kanabo Group PLC  17 January 2023

Kanabo Group Plc.

("Kanabo" or the "Company")

 

Launch of two new medical cannabis products

& testing of the new IT Cannabis Platform

 

 

Kanabo Group, is pleased to announce the launch of two new medical cannabis
extract formulas for inhalation, designed specifically to fill a gap in the
market for premium products for patients with severe pain. The new formulas,
available in versions suitable for day and evening use, will be branded as a
Kanabo-Noidecs partnership with LYPHE Group and used with the VapePod,
containing high levels of THC, low CBD, and cannabis naturally derived
terpenes. The launch will broaden Kanabo's vape offering to the market and is
an additional step for the company to build a robust product offering to all
eligible patients in the UK. These new formulas will be available from next
week to eligible patients via Dispensary Green pharmacy.

Further to the above, Kanabo Group is committed to increasing patient access
to prescribed medical cannabis in the UK by developing a new platform using
its recently acquired UK subsidiary, The GP Service Ltd. The company is
pleased to announce that all the regulatory approvals have been obtained, and
the testing stage of the platform has begun. Additional updates will be
provided in due course.

Dr Mehran Afshar, Clinical Director of Kanabo Group:

"We are committed to improving patient access to prescribed medical cannabis
through innovative technology and telemedicine services. Our new medical
cannabis extract formulas for inhalation offer patients suffering from severe
pain a premium option for managing their symptoms without the negative side
effects of traditional cannabis flowers."

 

 

For further information, please visit http://www.kanabogroup.com/
(http://www.kanabogroup.com/) :

 

 Kanabo Group Plc
 Avihu Tamir, CEO
 Peterhouse Capital Ltd (Financial Adviser)   Tel: +44 (0)20 7469 0930
 Eran Zucker
 Peterhouse Capital Ltd (Corporate Broker)
 Lucy Williams / Charles Goodfellow

 

About Kanabo Group Plc

Kanabo Group Plc is a leading developer and distributor of cannabis-derived
products and inhalation technologies for medical patients and wellness
consumers. The company is the first medicinal cannabis company to IPO on the
London Stock Exchange and is made up of supply-chain specialist subsidiaries,
including:

 

●   The GP Service - a Kanabo Group Plc wholly owned, NHS-approved online
telehealth provider offering video consultations, online prescriptions,
treatment forms and access to primary care services.

●   Kanabo Research Ltd - a wholly owned subsidiary responsible for Medical
Device Development, Medical Cannabis formulation R&D, regulation and
quality assurance procedures.

●   Kanabo Agritec Ltd - a partly owned subsidiary, Cannabis Grow
Consultancy firm that provides a comprehensive technology solution for
controlled farming, including state-of-the-art irrigation and fertigation
automation, facility planning and support services. This will provide
high-quality raw materials for Kanabo's formulas and product line.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PRLEAXFKFFDDEFA